Vesalio has today announced receipt of CE-mark approval for commercialisation of its new NeVa NET, which the company claims is the “first and only” thrombectomy device with an integrated clot microfiltration technology.
This unique stent retriever combines Vesalio’s proprietary Drop Zone technology, which—according to a company press release—is proven to work on all clot types, with a finely braided microfilter net element integrated into the closed distal tip of the device.
The NeVa NET’s integrated microfilter is designed to keep clot particles from escaping to new or distal territories, which has been reported to occur in up to 40% of cases, the release continues. With this innovative clot-retention technology, the new NeVa thrombectomy device carries an enhanced feature engineered to maximise clot retention.
This combination of patented technologies is designed to improve recanalisation quality, speed and distal embolisation protection to lead to even better patient outcomes, the release notes, adding that postmarket clinical studies are underway in select markets in Europe and will be followed by broader commercialisation in the European marketplace.
In the release, Vesalio also describes this recent CE marking of the NeVa NET as a “further expansion of [its] high-performance thrombectomy portfolio”.
“We are excited to continuously demonstrate our ability to bring clinically meaningful innovation to the market in response to critical unmet needs,” said Vesalio CEO Steve Rybka. “We expect the revolutionary NeVa NET to set a new standard of care in stroke thrombectomy, helping save lives and improve patient outcomes for many years to come.”
